GlobeNewswire·Nov 12, 2026, 10:00 AM ET

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

NTLA

Monthly attack rates decreased by 81% in HAELO Phase 3 patients previously on long-term prophylaxis after receiving lonvo-z dosing.
100% of patients receiving 50 mg of lonvo-z across Phase 1/2 trials and the HAELO study were long-term prophylaxis-free as of data cutoffs.
96% of interviewed Phase 1/2 patients described lonvo-z as an optimal therapy, with all reporting their hereditary angioedema as well-controlled post-treatment.
Four-year data showed consistent plasma kallikrein reductions averaging 84% at four weeks, maintained through up to four years of follow-up without new long-term safety risks.
Over four years of Phase 1/2 follow-up, at least 90% of patients remained attack-free monthly after a single 50 mg dose, with the probability of an attack-free interval exceeding six months rising from 81% to 93%.
In the HAELO Phase 3 trial, 63% of patients on prior long-term prophylaxis achieved complete control following lonvo-z, more than tripling previous attack-free rates.
Quality of life improvements were sustained, with lonvo-z recipients showing a 23.5-point reduction in AE-QoL scores compared to a 6.5-point reduction for placebo.
An integrated analysis of 93 patients across all phases revealed an 89% overall attack rate reduction, with 97% never initiating long-term prophylaxis after treatment.
The FDA accepted the Biologics License Application for lonvo-z in September 2026, granting Priority Review with a target action date of March 10, 2027.
Intellia Therapeutics will host an investor webcast on November 12, 2026, at 10:00 a.m. ET to discuss these data points and commercial launch preparations.

Company: Intellia Therapeutics, Inc.
Keywords: Nasdaq:NTLA, Intellia Therapeutics, Inc.